5,524 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Quantessence Capital LLC

Quantessence Capital LLC purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,524 shares of the medical equipment provider's stock, valued at approximately $584,000.

A number of other institutional investors have also modified their holdings of ZBH. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $473,000. KLCM Advisors Inc. bought a new stake in Zimmer Biomet in the fourth quarter valued at $7,825,000. Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at $654,000. Van ECK Associates Corp grew its position in shares of Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the last quarter. Finally, Reinhart Partners LLC. increased its holdings in shares of Zimmer Biomet by 34.4% in the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock worth $9,164,000 after acquiring an additional 22,220 shares during the period. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Down 1.6 %

Shares of NYSE ZBH opened at $96.38 on Tuesday. The stock has a market cap of $19.07 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 52 week low of $93.10 and a 52 week high of $123.96. The business has a 50 day simple moving average of $105.87 and a 200 day simple moving average of $106.68. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the business posted $2.20 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.00%. Zimmer Biomet's payout ratio is 21.57%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.95% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Finally, Truist Financial reissued a "hold" rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.